New Platinum Agents

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

1989 • 1,831 citations

Estimates of the worldwide frequency of sixteen major cancers in 1980

1988 • 1,073 citations

Cisplatin

1984 • 942 citations

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

1991 • 824 citations

Charles F. Kettring prize. Fundamental studies with cisplatin

1985 • 514 citations

Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

1986 • 496 citations

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

1991 • 438 citations

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1990 • 384 citations

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

1992 • 369 citations

Molecular Aspects of Anticancer Drug-DNA Interactions

1994 • 351 citations

Phase I study of oxaliplatin in patients with advanced cancer

1990 • 340 citations

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

1992 • 292 citations

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

1991 • 291 citations

Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer

1990 • 287 citations

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1993 • 275 citations

Preclinical studies identifying carboplatin as a viable cisplatin alternative

1985 • 246 citations

New platinum antitumor complexes

1993 • 235 citations

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

1993 • 226 citations

High-dose cisplatin in hypertonic saline in refractory ovarian cancer.

1985 • 225 citations

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

1992 • 211 citations

Long-term survival in ovarian cancer

1991 • 210 citations

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.

1993 • 193 citations

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes

1989 • 184 citations

Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.

1976 • 179 citations

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

1994 • 166 citations

Modulation of cis-diamminedichloroplatinum(II) resistance: a review

1992 • 161 citations

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes

1992 • 160 citations

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1992 • 159 citations

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.

1992 • 137 citations

Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin

1989 • 137 citations

Phase I studies with carboplatin at the Royal Marsden Hospital

1985 • 133 citations

A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.

1994 • 129 citations

Cisplatin/carboplatin cross-resistance in ovarian cancer

1989 • 115 citations

A Comparison of the Toxicity and Efficacy of Cisplatin and Carboplatin in Advanced Ovarian Cancer

1989 • 111 citations

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin

1993 • 111 citations

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

1994 • 98 citations

Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer

1988 • 91 citations

Rationale for development of platinum analogs.

1979 • 86 citations

The current status of new platinum analogs.

1992 • 80 citations

Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.

1994 • 79 citations

Cancer chemotherapy : challenges for the future

1987 • 78 citations

Ovarian cancer: new clinical approaches

1991 • 62 citations

Cyclophosphamide-Cisplatin Versus Cyclophosphamide-Carboplatin in Stage III-IV Ovarian Carcinoma: A Comparison of Equally Myelosuppressive Regimens

1989 • 60 citations

Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.

1991 • 59 citations

Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.

1994 • 46 citations

Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.

1992 • 43 citations

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

1993 • 43 citations

Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat.

1994 • 43 citations

A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.

1991 • 34 citations

Phase II study of iproplatin in advanced ovarian carcinoma.

1988 • 31 citations

The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: A cautionary note

1991 • 31 citations

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts

1993 • 29 citations

Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study

1991 • 24 citations

High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.

1990 • 24 citations

A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP

1990 • 23 citations

High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.

1993 • 23 citations

Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin?

1992 • 22 citations

Carboplatin in the first-line chemotherapy of ovarian cancer.

1990 • 22 citations

Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates

1994 • 21 citations

Studies on the human metabolism of iproplatin

1989 • 20 citations

New Platinum Drugs

1993 • 13 citations

Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.

1992 • 11 citations

Molecular aspects of anticancer drug-DNA interactions (vol. 1)

1994 • 10 citations

New developments with carboplatin in the treatment of ovarian cancer.

1992 • 10 citations

Ammine/amine platinum (IV) dicarboxylates: A lead to the discovery of a new generation of broad spectrum platinum-based anticancer drugs

1993 • 5 citations

Non-surgical aspects of ovarian cancer.

1994 • 4 citations